How much money could the federal government save if the US Federal Trade Commission launched a campaign against brand-name drug makers seeking to delay generic competition through product-hopping? The Congressional Budget Office puts the figure at half a billion dollars over the next decade.
That seems like a big number, something pharma really needs to worry about – until you consider that the comprehensive...







